Bill > HB4789

This bill amends the existing "Right to Try Act" to expand patient access to experimental medical treatments, specifically introducing a new category called "individualized investigational treatment" which refers to treatments uniquely produced for a patient based on their personal genetic analysis. The bill broadens the definition of eligible patients to include those with life-threatening or severely debilitating illnesses, not just advanced illnesses, and allows patients to access investigational drugs, biological products, or devices that have completed phase 1 clinical trials but are not yet FDA-approved. The legislation protects healthcare providers from professional disciplinary actions for recommending these treatments and ensures that manufacturers are not required to provide the treatments but may do so with or without compensation. The bill also clarifies that health insurers and government agencies are not obligated to cover the costs of these experimental treatments, and it protects patients' heirs from being liable for outstanding medical debt if a patient dies while receiving such treatment. Importantly, the bill establishes that no private cause of action can be brought against manufacturers or healthcare providers if they act in good faith and exercise reasonable care when providing these investigational treatments.

Health and Social Services

https://legislature.mi.gov/Bills/Bill?ObjectName=2025-HB-4789